 Dr. Scot Simpson (University of Alberta, Edmonton), at the European Association for the Study of Diabetes(EASD) 2012 Annual Meeting, reported that rates of ACS-related hospitalization or death were higher among patients taking glyburide than those taking gliclazide.
Simpson and colleagues reviewed administrative health records for the province of Alberta, Canada, identifying more than 11,000 diabetic patients using either gliclazide or glyburide who also had a history of ischemic heart disease. Over 1000 person-years, researchers saw 99.6 ACS-related hospitalizations or deaths among patients taking glyburide and 88.9 among patients taking gliclazide as their only sulfonylurea. The difference was small but statistically different (p<0.05), Simpson stressed. ACS-related hospitalizations were also slightly higher among glyburide users (87.7 vs 78.1; p<0.05). ACS-related deaths were not statistically different.
|
Previous | Home | Next 
